Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY4 known ✓ | P51582 | 7/20 | 0.71 |
| ▸ | P2RY2 known ✓ | P41231 | 6/20 | 0.71 |
| ▸ | P2RY12 known ✓ | Q9H244 | 5/20 | 0.71 |
| ▸ | P2RY1 known ✓ | P47900 | 1/20 | 0.69 |
| ▸ | P2RY6 known ✓ | Q15077 | 1/20 | 0.69 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.78 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.78 |
| ▸ | CDK2 | P24941 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792522 | 1.00 | ENTPD1 (0.78) | ENTPD1ENTPD2P2RY4P2RY2P2RY12 | |
| SCHEMBL31268442 | 0.87 | ENTPD1 (1.00) | ENTPD1ENTPD2P2RY4P2RY2P2RY12 | |
| SCHEMBL29354313 | 0.87 | GNG2 (0.66) | ENTPD1ENTPD2P2RY4P2RY2P2RY12 | |
| SCHEMBL13214120 | 0.87 | GNG2 (0.66) | ENTPD1ENTPD2P2RY4P2RY2P2RY12 | |
| SCHEMBL3032350 | 0.87 | P2RY4 (0.80) | P2RY4P2RY2P2RY12CDK2P2RY1 | |
| SCHEMBL792523 | 0.86 | GNG2 (0.65) | ENTPD1ENTPD2P2RY4P2RY2P2RY12 | |
| SCHEMBL3033638 | 0.85 | P2RY12 (0.80) | P2RY4P2RY2P2RY12CDK2P2RY1 | |
| SCHEMBL3022506 | 0.83 | P2RY12 (1.00) | ENTPD1P2RY4P2RY2P2RY12CDK2 | |
| SCHEMBL3025505 | 0.83 | P2RY12 (1.00) | P2RY4P2RY2P2RY12CDK2P2RY1 | |
| SCHEMBL3032357 | 0.82 | P2RY12 (0.77) | ENTPD1ENTPD2P2RY4P2RY2P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024259358-A2 | MODULATION OF FUSOBACTERIUM NUCLEATUM SUBSPECIES ANIMALIS CLADE 2 MICROBES | FRED HUTCHINSON CANCER CENTER (US) | 2024-12-19 | — | — | WO | claimed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | claimed |
| EP-2943564-B1 | SL327 FOR USE IN SKIN REGENERATION | INT STEM CELL CORPORATION (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4698901-A1 | MARKERS FOR PREDICTING THERAPEUTIC EFFICACY OF A T CELL | Charité - Universitätsmedizin Berlin (DE) | 2026-02-25 | — | — | EP | disclosed |
| EP-3908601-B1 | COMPOSITIONS FOR TREATING CANCER | OMEROS CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024259358-A2 | MODULATION OF FUSOBACTERIUM NUCLEATUM SUBSPECIES ANIMALIS CLADE 2 MICROBES | FRED HUTCHINSON CANCER CENTER (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024218318-A1 | MARKERS FOR PREDICTING THERAPEUTIC EFFICACY OF A T CELL | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2024-10-24 | — | — | WO | disclosed |
| US-20240307537-A1 | Methods and Compositions for Treating Cancer | OMEROS CORPORATION | 2024-09-19 | — | — | US | disclosed |
| EP-4412711-A1 | SERUM HALF-LIFE EXTENDED PD-L1 BINDING POLYPEPTIDES | Avacta Life Sciences Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| EP-4413038-A1 | PD-L1 BINDING AFFIMERS | Avacta Life Sciences Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| EP-4126053-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115697413-A | Radiopharmaceuticals and imaging agents targeting FAP and uses related thereto | 塔夫茨大学信托人 | 2023-02-03 | — | — | CN | disclosed |
| US-20220370647-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2022-11-24 | — | — | US | disclosed |
| WO-2022234003-A1 | CD33 BINDING POLYPEPTIDES WITH STEFIN A PROTEIN | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022204368-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2022-07-07 | — | — | US | disclosed |
| WO-2022133288-A1 | FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022050230-A1 | COMPOSITION INHIBITING ACTIVATION OF ADENOSINE RECEPTOR | 学校法人埼玉医科大学 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307537-A1 | Methods and Compositions for Treating Cancer | LPAR5, LPAR3, LPAR1 | P2RY4 712/4885P2RY2 565/4885P2RY12 1463/4885 |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | P2RY4 3163/4885P2RY2 2965/4885P2RY12 2756/4885 |
| US-20220370647-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | P2RY4 819/4885P2RY2 1211/4885P2RY12 1029/4885 |
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | FAP, FIBP, FGFR1 | P2RY4 1096/4885P2RY2 1345/4885P2RY12 1446/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | P2RY4 3579/4885P2RY2 3280/4885P2RY12 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.